1 rich Libsyn https://www.libsyn.com 300 600 💊 Can weight loss achieved with injectable GLP-1 therapies be maintained using an oral agent? &amp;nbsp; The ATTAIN-MAINTAIN phase 3b trial published in Nature Medicine evaluated once-daily oral orforglipron after prior tirzepatide or semaglutide therapy. Patients maintained substantially more prior weight reduction versus placebo over 52 weeks, while preserving cardiometabolic benefits. 🌍⚖️ &amp;nbsp; A fascinating glimpse into the future of scalable obesity care: oral incretin therapy may improve adherence, accessibility, and long-term maintenance. &amp;nbsp; #Obesity #GLP1 #Orforglipron #NatureMedicine #Cardiology #Endocrinology #MedicalPodcast #PhysicianEducation Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity! http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/41326505/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/202051660